By otakuyassine3@gmail.com 
Amundi lifted its position in Embecta Corp. (NASDAQ:EMBC – Free Report) by 161.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,287 shares of the company’s stock after acquiring an additional 19,925 shares during the quarter. Amundi’s holdings in Embecta were worth $655,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in EMBC. Garden State Investment Advisory Services LLC acquired a new stake in shares of Embecta during the 3rd quarter worth approximately $438,000. Barclays PLC raised its position in shares of Embecta by 41.1% during the 3rd quarter. Barclays PLC now owns 97,930 shares of the company’s stock worth $1,381,000 after purchasing an additional 28,523 shares during the period. Jennison Associates LLC acquired a new stake in shares of Embecta during the 3rd quarter worth approximately $594,000. Jane Street Group LLC raised its position in shares of Embecta by 156.1% during the 3rd quarter. Jane Street Group LLC now owns 176,487 shares of the company’s stock worth $2,488,000 after purchasing an additional 107,567 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Embecta by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company’s stock worth $19,564,000 after purchasing an additional 45,228 shares during the period. Institutional investors and hedge funds own 93.83% of the company’s stock.
Embecta Trading Up 1.1 %
Shares of NASDAQ EMBC opened at $13.63 on Thursday. Embecta Corp. has a 12-month low of $9.93 and a 12-month high of $21.48. The company has a market cap of $792.37 million, a PE ratio of 13.63, a P/E/G ratio of 0.78 and a beta of 1.27. The stock has a 50 day simple moving average of $16.22 and a 200-day simple moving average of $16.42.
Embecta (NASDAQ:EMBC – Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Sell-side analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.
Embecta Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were paid a dividend of $0.15 per share. The ex-dividend date was Friday, February 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.40%. Embecta’s dividend payout ratio is presently 60.00%.
Wall Street Analyst Weigh In
EMBC has been the topic of a number of research reports. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target on the stock in a research report on Wednesday, November 27th. Morgan Stanley upgraded Embecta from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.
Check Out Our Latest Research Report on EMBC
Insider Activity at Embecta
In related news, Director Milton Mayo Morris sold 3,100 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the transaction, the director now owns 36,133 shares in the company, valued at $591,858.54. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.42% of the company’s stock.
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes.
Featured Articles
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Free Report).
Receive News & Ratings for Embecta Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Embecta and related companies with MarketBeat.com’s FREE daily email newsletter.